A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

被引：6
|
作者：
Bauer, S. [1 ]
Demetri, G. [2 ]
Jeay, S. [3 ]
Dummer, R. [4 ]
Guerreiro, N. [3 ]
Tan, D. S. [5 ]
Kumar, A. [6 ]
Meille, C. [3 ]
Van Bree, L. [3 ]
Halilovic, E. [7 ]
Wuerthner, J. U. [3 ]
Cassier, P. [8 ]
机构：
[1] Univ Klinikum Essen, Internal Med, Essen, Germany
[2] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Univ Zurich Hosp, Zurich, Switzerland
[5] Natl Canc Ctr, Singapore, Singapore
[6] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[7] Novartis Inst BioMed Res, Cambridge, MA USA
[8] Ctr Leon Berard, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366PD
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
    Kollmannsberger, C.
    Hirte, H.
    Siu, L. L.
    Mazurka, J.
    Chi, K.
    Elit, L.
    Walsh, W.
    Sederias, J.
    Doyle, A.
    Eisenhauer, E. A.
    Oza, A. M.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 238 - 244
  • [42] A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yamamoto, Noboru
    CLINICAL LUNG CANCER, 2023, 24 (02) : e65 - e68
  • [43] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S69 - S70
  • [44] A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
    Shapiro, Geoffrey
    Supko, Jeffrey G.
    Cho, Daniel C.
    Hilton, John Frederick
    Hadfield, Matthew
    Pruitt-Thompson, Salida
    Bordoli-Trachsela, Eveline
    Zvereva, Nela
    Wolanski, Andrew
    Sato-DiLorenzo, Aya
    Gotthardt, Susan
    Fox, Edward A.
    Verselis, Sigitas Jonas
    Kumar, Ashok
    Holden, Sylvia A.
    Ram, Siya
    Chafai-Fadela, Karima
    Harding, Kimberly
    Menon, Krishna E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [46] A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and IV Bortezomib in Patients with Relapsed Multiple Myeloma.
    San-Miguel, Jesus F.
    Sezer, Orhan
    Siegel, David
    Guenther, Andreas
    Mateos, Maria-Victoria
    Prosser, Ian
    Cavo, Michele
    Blade, Joan
    Boccadoro, Mario
    Bengoudifa, Bourras R.
    Klebsattel, Martin
    Bourquelot, Priscille M.
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1481 - 1482
  • [47] Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS)
    Hartner, L. P.
    Rosen, L.
    Hensley, M.
    Mendelson, D.
    Staddon, A. P.
    Chow, W.
    Kovalyov, O.
    Ruka, W.
    Skladowski, K.
    Jagiello-Gruszfeld, A.
    Byakhov, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
    Pitot, Henry C.
    Hurwitz, Herbert
    Zanna, Claudio
    Brill, Jeffrey Mark
    Vuagniaux, Gregoire
    Rouits, Elisabeth
    Sorensen, J. Mel
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
    Cheng, A-L.
    Yen, C-J.
    Okusaka, T.
    Ikeda, M.
    Hsu, C-H.
    Wu, S-Y.
    Morizane, C.
    Hashimoto, Y.
    Ueshima, K.
    Ohtomo, T.
    Tanaka, T.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study
    Schaff, Lauren R.
    Lobbous, Mina
    Carlow, Dean
    Schofield, Ryan
    Gavrilovic, Igor T.
    Miller, Alexandra M.
    Stone, Jacqueline B.
    Piotrowski, Anna F.
    Sener, Ugur
    Skakodub, Anna
    Acosta, Edward P.
    Ryan, Kevin J.
    Mellinghoff, Ingo K.
    DeAngelis, Lisa M.
    Nabors, Louis B.
    Grommes, Christian
    BMC CANCER, 2022, 22 (01)
12345